ERBB2 and breast carcinoma: Our previously proposed panel consisting of CD44v6, EGFR, HER2, IGF1-R, and GLUT1 for imaging of female breast cancer was significantly less sensitive for imaging of male breast cancer (female breast cancer 79.3% vs. male breast cancer 69.1%, p = 0.025; Figure 2A).